Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

) where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). He currently serves on the Board of Directors for several life sciences companies including Inhibitex, Inc. and Targacept, Inc.

Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.

Shire HGT Collaboration

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders: Amigal, Plicera and AT2220. Under the terms of the collaboration, Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay tiered, double-digit royalties on net sales of the products. Shire also reimburses worldwide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended June 30, 2009, was $13.6 million as compared to $9.3 million for the same period in 2008. On a non-GAAP basis, the net loss for the three months ended June 30, 2009, was $11
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... with financial software provider BlackLine Systems  and enterprise ... SAP ) for a webinar next week entitled "No ... from BlackLine and SAP to Help Keep Its Account Reconciliations ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at finance, ...
(Date:6/19/2013)... Canada (PRWEB) June 19, 2013 ... trial business can potentially be worth up to ... this opportunity, the Indian government is taking serious ... trials the process. , This presentation will examine:, ... trial regulations ,     Immediate and long term ...
(Date:6/19/2013)... June 19, 2013 Express Diagnostics Int’l, ... today announced that it has received Class III medical ... sell its DrugCheck® NxStep Onsite Drug Screen Cup ... the rapid screening device in near-patient settings, such as ... Cup received Health Canada Class III approval for 24 ...
(Date:6/18/2013)... A million electric cars could be on roads across ... help of research by the United States Department of Energy, ... Professor Zhongwei Chen is part of a team led by ... to replace the expensive platinum catalysts in fuel cells. , ... cells in vehicles is the cost of the units. The ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2
... July 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), ... agreement to exclusively license seven cancer antigens from ... antigens specifically target breast, ovarian and prostate cancers. ... DepoVax(TM) delivery platform to develop DPX-0907, a therapeutic ...
... , , TAMPA, Fla., July 14 ... the research and development of cancer immunotherapies, announces that the first ... dendritic cell therapy. , , ... clinical trial testing the safety and efficacy of its immunotherapy on ...
... , , ... biotechnology company delivering breakthrough therapies in central nervous system ... the efficacy of the ketogenic compound AC-1202 (Axona(TM)) in ... completed double-blind, placebo-controlled trial in patients with mild-to-moderate Alzheimer,s ...
Cached Biology Technology:ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 2Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 3Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 4
(Date:6/19/2013)... paper published in the journal Polar Biology, researchers report using ... may be a new type of killer whale ( Orcinus ... unusual-looking killer whales stranded on a New Zealand beach and ... were also taken but it was almost 50 years before ... small white eye-patch and bulbous forehead, was documented alive in ...
(Date:6/19/2013)... Insulin is the most potent physiological anabolic agent ... and synthesis of lipids, protein and carbohydrates, and ... system. It also plays a major role in ... glucose is metabolized and removed from the blood ... precise molecular mechanisms by which insulin regulates glucose ...
(Date:6/19/2013)... the Midwest are expected to contribute to a very ... zone," according to a University of Michigan ecologist and ... one for the Chesapeake Bay. , The Gulf forecast, ... Atmospheric Administration, calls for an oxygen-depleted, or hypoxic, region ... place it among the 10 largest on record. , ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... plant,s defences and causes disease,by sneakily disabling the plant,s ... (4 December) in Current Biology . ... causes bacterial speck disease,in tomato plants. This bacterial invasion ... cause extensive and costly damage to,tomato crops, and researchers ...
... half of a person,s body mass consisting of skeletal ... those found in the limbs can result in ... kinesiology and community health professor Kimberly Huey, past research ... may be associated with reduced expression of certain pro-inflammatory ...
... earthquakes and destructive tsunamis over the past four years is ... warns an international group of earthquake researchers in their paper ... Nature . , The first of the recent great earthquakes, ... and destructive tsunami in living memory. The cause of ...
Cached Biology News:Red alert! How disease disables tomato plant's 'intruder alarm' 2Vitamin E shows possible promise in easing chronic inflammation 2Vitamin E shows possible promise in easing chronic inflammation 3September 2007 Sumatran earthquakes research findings 2September 2007 Sumatran earthquakes research findings 3
... package is used for determining protein concentration in ... RC DC protein assay is a colorimetric assay. ... assays: 250 ml RC reagent I, 250 ml ... solution, 2 L dilute Folin reagent, and 5 ...
... SureLINK Bioconjugation Kit provides a powerful yet ... and nuceleic acids. The kit provides the ... reagents for quantifying conjugation efficiencies. It enables ... biotin and other tags with a variety ...
...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Biology Products: